Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...

Bristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers look to ...

By Michael Erman and Ludwig Burger (Reuters) -Bristol Myers Squibb will pay $1.5 billion upfront to partner with Germany's ...

By Michael Erman and Ludwig Burger (Reuters) -Bristol Myers Squibb has agreed to pay up to $11.1 billion in a partnership ...

The deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

Meanwhile, BioNTech itself bought into the category with its takeover of BNT327's developer Biotheus unit last year for what ...

Western drugmakers, investors increasingly aim to acquire Chinese compounds.

Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7 ...

The US’s policy under the Second Donald Trump Administration has undergone major changes, with experts saying that America is ...